{
    "paper_id": "b8de9e9be00cfed1ff64c5c6dff807373120d7da",
    "metadata": {
        "title": "Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV- 1 SARS-CoV-2 and a clinical isolate of SARS-CoV-2. 2 3",
        "authors": [
            {
                "first": "James",
                "middle": [
                    "Brett"
                ],
                "last": "Case",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Paul",
                "middle": [
                    "W"
                ],
                "last": "Rothlauf",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Rita",
                "middle": [
                    "E"
                ],
                "last": "Chen",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Zhuoming",
                "middle": [],
                "last": "Liu",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Haiyan",
                "middle": [],
                "last": "Zhao",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Arthur",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "S",
                "middle": [],
                "last": "Kim",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Louis-Marie",
                "middle": [],
                "last": "Bloyet",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Qiru",
                "middle": [],
                "last": "Zeng",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Stephen",
                "middle": [],
                "last": "Tahan",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Lindsay",
                "middle": [],
                "last": "Droit",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Ma",
                "middle": [],
                "last": "Xenia",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "G",
                "middle": [],
                "last": "Ilagan",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Michael",
                "middle": [
                    "A"
                ],
                "last": "Tartell",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Gaya",
                "middle": [],
                "last": "Amarasinghe",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Jeffrey",
                "middle": [
                    "P"
                ],
                "last": "Henderson",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Shane",
                "middle": [],
                "last": "Miersch",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Toronto",
                    "location": {
                        "addrLine": "13",
                        "settlement": "Toronto",
                        "country": "Canada"
                    }
                },
                "email": ""
            },
            {
                "first": "Mart",
                "middle": [],
                "last": "Ustav",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Sachdev",
                "middle": [],
                "last": "Sidhu",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Toronto",
                    "location": {
                        "addrLine": "13",
                        "settlement": "Toronto",
                        "country": "Canada"
                    }
                },
                "email": ""
            },
            {
                "first": "Herbert",
                "middle": [
                    "W"
                ],
                "last": "Virgin",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "David",
                "middle": [],
                "last": "Wang",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Siyuan",
                "middle": [],
                "last": "Ding",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Davide",
                "middle": [],
                "last": "Corti",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Humabs 14 BioMed SA, a subsidiary of Vir Biotechnology, Inc., CH-6500",
                    "institution": "",
                    "location": {
                        "settlement": "Bellinzona",
                        "country": "Switzerland"
                    }
                },
                "email": ""
            },
            {
                "first": "Elitza",
                "middle": [
                    "S"
                ],
                "last": "Theel",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Toronto",
                    "location": {
                        "addrLine": "13",
                        "settlement": "Toronto",
                        "country": "Canada"
                    }
                },
                "email": ""
            },
            {
                "first": "Daved",
                "middle": [
                    "H"
                ],
                "last": "Fremont",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Michael",
                "middle": [
                    "S"
                ],
                "last": "Diamond",
                "suffix": "",
                "affiliation": {},
                "email": "diamond@wusm.wustl.edu"
            },
            {
                "first": "Sean",
                "middle": [
                    "P J"
                ],
                "last": "Whelan",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Michael",
                "middle": [
                    "S"
                ],
                "last": "20 Diamond",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "Antibody-based interventions against SARS-CoV-2 could limit morbidity, mortality, and 26 possibly disrupt epidemic transmission. An anticipated correlate of such countermeasures is the 27 level of neutralizing antibodies against the SARS-CoV-2 spike protein, yet there is no consensus 28 as to which assay should be used for such measurements. Using an infectious molecular clone 29 of vesicular stomatitis virus (VSV) that expresses eGFP as a marker of infection, we replaced the 30 glycoprotein gene (G) with the spike protein of SARS-CoV-2 (VSV-eGFP-SARS-CoV-2) and 31 developed a high-throughput imaging-based neutralization assay at biosafety level 2. We also 32 developed a focus reduction neutralization test with a clinical isolate of SARS-CoV-2 at biosafety 33 level 3. We compared the neutralizing activities of monoclonal and polyclonal antibody 34 preparations, as well as ACE2-Fc soluble decoy protein in both assays and find an exceptionally 35 high degree of concordance. The two assays will help define correlates of protection for antibody-36 based countermeasures including therapeutic antibodies, immune \u03b3-globulin or plasma 37 preparations, and vaccines against SARS-CoV-2. Replication-competent VSV-eGFP-SARS-38",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "4 (Hoffmann et al., 2020; Lei et al., 2020; Ou et al., 2020) . Such pseudotyping approaches are used 68 routinely by many laboratories for other highly pathogenic coronaviruses including SARS-CoV 69 and MERS-CoV (Fukushi et al., 2006; Fukushi et al., 2005; Giroglou et al., 2004; Kobinger et al., ",
            "cite_spans": [
                {
                    "start": 2,
                    "end": 25,
                    "text": "(Hoffmann et al., 2020;",
                    "ref_id": null
                },
                {
                    "start": 26,
                    "end": 43,
                    "text": "Lei et al., 2020;",
                    "ref_id": null
                },
                {
                    "start": 44,
                    "end": 60,
                    "text": "Ou et al., 2020)",
                    "ref_id": null
                },
                {
                    "start": 212,
                    "end": 234,
                    "text": "(Fukushi et al., 2006;",
                    "ref_id": null
                },
                {
                    "start": 235,
                    "end": 256,
                    "text": "Fukushi et al., 2005;",
                    "ref_id": null
                },
                {
                    "start": 257,
                    "end": 279,
                    "text": "Giroglou et al., 2004;",
                    "ref_id": null
                },
                {
                    "start": 280,
                    "end": 296,
                    "text": "Kobinger et al.,",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "INTRODUCTION"
        },
        {
            "text": "Here, we developed a simple and robust BSL2 assay for evaluating SARS-CoV-2 entry 82 and its inhibition by antibodies. We engineered an infectious molecular clone of vesicular 83 stomatitis virus (VSV) to encode the SARS-CoV-2 S protein in place of the native envelope 84 glycoprotein (G) and rescued an autonomously replication-competent virus bearing the spike.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "81"
        },
        {
            "text": "Through passage of VSV-eGFP-SARS-CoV-2, we selected a gain-of-function mutation in S that 86 allowed more efficient viral propagation yielding titers of > 1 x 10 8 plaque-forming units (PFU)/ml.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "85"
        },
        {
            "text": "We characterized this variant with respect to inhibition by soluble human ACE2-Fc and 88 monoclonal and polyclonal antibodies from humans and compared those results to neutralization 89 tests with a clinical isolate of SARS-CoV-2. These studies demonstrate that a recombinant VSV 90 expressing SARS-CoV-2 S behaves analogously to a clinical isolate of SARS-CoV-2, providing a 91 useful high-throughput BSL2 assay for studying antibody neutralization or inhibition of viral spike-92 mediated entry.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "87"
        },
        {
            "text": "A replication-competent, infectious VSV chimera with SARS-CoV-2 S protein. To 95 generate a replication-competent virus to study entry and neutralization of SARS-CoV-2 at BSL2, 96 we engineered an infectious molecular clone of VSV by replacing the endogenous glycoprotein 97 (G) with SARS-CoV-2 S (Fig 1A) . SARS-CoV-2 S protein contains an endoplasmic reticulum (ER) 98 retention sequence in the cytoplasmic tail (KxHxx-COOH) because virion assembly occurs in ER-",
            "cite_spans": [
                {
                    "start": 363,
                    "end": 367,
                    "text": "(ER)",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 297,
                    "end": 305,
                    "text": "(Fig 1A)",
                    "ref_id": "FIGREF17"
                }
            ],
            "section": "94"
        },
        {
            "text": "Golgi intermediate compartments (Lontok et al., 2004; McBride et al., 2007; Ruch and Machamer, 100 2012). We preemptively altered that sequence to AxAxx to facilitate retargeting of S to the plasma 101 membrane, the site of VSV assembly. Using established approaches (Fig S1A) (Whelan et al., 102 1995), we recovered infectious VSV-eGFP-SARS-CoV-2-SAA as determined by expression of the 103 virus-encoded eGFP reporter (Fig 1A, right panel) . VSV-eGFP-SARS-CoV-2-SAA propagation 104 was inefficient on Vero CCL81 cells. This result prompted us to test additional modifications of 105 the cytoplasmic tail of S, which were also defective in autonomous amplification (Fig S1B) . To 106 overcome this limitation, we used a forward genetic approach to isolate an adaptive variant of 107 VSV-eGFP-SARS-CoV-2-SAA ( Fig S1C) . Repeated passage and plaque isolation on Vero CCL81 108 cells led to the emergence of a virus that contained a cysteine to stop mutation at residue 1253 109 (TGC to TGA at nucleotide 3759), which truncates the cytoplasmic tail of SARS-CoV-2 S by 21 110 residues (Fig 1A) . We confirmed that this was the only mutation in the viral genome by next 111 generation sequencing (Supplemental Data). Comparison of plaque morphology of VSV-eGFP-112 SARS-CoV-2-S\u039421 and VSV-eGFP-SARS-CoV-2-SAA on three Vero cell subtypes and an 113 additional rhesus monkey cell line (MA104) demonstrates that the selected variant spreads more 114 efficiently (Fig 1B) . Screening of a larger panel of cell types (Fig 1C) identified MA104 and Vero 115 E6 cells as supporting the highest levels of virus production. Ectopic expression of TMPRSS2 led 116 to a further ~10-fold increase in viral titer and a larger plaque size (Fig 1D) .",
            "cite_spans": [
                {
                    "start": 32,
                    "end": 53,
                    "text": "(Lontok et al., 2004;",
                    "ref_id": null
                },
                {
                    "start": 54,
                    "end": 75,
                    "text": "McBride et al., 2007;",
                    "ref_id": null
                },
                {
                    "start": 76,
                    "end": 94,
                    "text": "Ruch and Machamer,",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 277,
                    "end": 292,
                    "text": "(Whelan et al.,",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 267,
                    "end": 276,
                    "text": "(Fig S1A)",
                    "ref_id": "FIGREF17"
                },
                {
                    "start": 419,
                    "end": 440,
                    "text": "(Fig 1A, right panel)",
                    "ref_id": "FIGREF17"
                },
                {
                    "start": 665,
                    "end": 674,
                    "text": "(Fig S1B)",
                    "ref_id": "FIGREF17"
                },
                {
                    "start": 809,
                    "end": 817,
                    "text": "Fig S1C)",
                    "ref_id": "FIGREF17"
                },
                {
                    "start": 1082,
                    "end": 1090,
                    "text": "(Fig 1A)",
                    "ref_id": "FIGREF17"
                },
                {
                    "start": 1455,
                    "end": 1463,
                    "text": "(Fig 1B)",
                    "ref_id": "FIGREF17"
                },
                {
                    "start": 1508,
                    "end": 1516,
                    "text": "(Fig 1C)",
                    "ref_id": "FIGREF17"
                },
                {
                    "start": 1719,
                    "end": 1727,
                    "text": "(Fig 1D)",
                    "ref_id": "FIGREF17"
                }
            ],
            "section": "99"
        },
        {
            "text": "incorporation of SARS-CoV-2 S into particles, we first amplified the virus in the presence of VSV 119 6 G to allow infection of cell types independently of the S protein. The VSV G trans-complemented 120 VSV-SARS-CoV-2-S\u039421 efficiently infects HEK293T cells, which then serve as a source of 121 production of virus particles containing SARS-CoV-2 S protein. Western blotting of supernatants 122 with CR3022, a cross-reactive anti-S monoclonal antibody (mAb) (ter Meulen et al., 2006; Yuan 123 et al., 2020) , established the presence of S\u039421 in VSV-SARS-CoV-2-S\u039421 particles but not in the 124 parental VSV (Fig 1E) . The protein detected migrated at ~100 kilodaltons, a band that 125 corresponds to the cleaved S1 subunit of the glycoprotein (Watanabe et al., 2020) . To examine 126 whether the S\u039421 incorporated into VSV particles is processed to S1 and S2, we performed [ 35 S] 127 cysteine-methionine metabolic labeling in BSRT7 cells, which support robust VSV replication, and 128 analyzed released particles by SDS-PAGE and phosphorimaging. In addition to the VSV 129 structural proteins (N, P, M and L), two additional bands were observed for VSV-SARS-CoV-2-130 S\u039421 that correspond in size to glycosylated S1 (107 kDa) and S2\u039421 (85 kDa) (Fig 1F) . Negative-131 stain electron microscopy of sucrose-gradient purified virus particles revealed that the membrane 132 protein projecting from VSV-SARS-CoV-2-S\u039421 is larger than observed on wild-type VSV particles 133 (Fig 1G) , which reflects the larger size of the coronavirus spike.",
            "cite_spans": [
                {
                    "start": 458,
                    "end": 483,
                    "text": "(ter Meulen et al., 2006;",
                    "ref_id": null
                },
                {
                    "start": 484,
                    "end": 506,
                    "text": "Yuan 123 et al., 2020)",
                    "ref_id": null
                },
                {
                    "start": 743,
                    "end": 766,
                    "text": "(Watanabe et al., 2020)",
                    "ref_id": "BIBREF29"
                }
            ],
            "ref_spans": [
                {
                    "start": 607,
                    "end": 615,
                    "text": "(Fig 1E)",
                    "ref_id": "FIGREF17"
                },
                {
                    "start": 1246,
                    "end": 1254,
                    "text": "(Fig 1F)",
                    "ref_id": "FIGREF17"
                },
                {
                    "start": 1471,
                    "end": 1479,
                    "text": "(Fig 1G)",
                    "ref_id": "FIGREF17"
                }
            ],
            "section": "118"
        },
        {
            "text": "A high-throughput focus-forming assay with a clinical isolate of SARS-CoV-2. VSV-135 SARS-CoV-2-S\u039421 has several advantages for detection and measuring of neutralizing antibodies, 136 including lower biosafety containment level, ease of production and use, and rapid reporter gene 137 readout. Nonetheless, the difference in virus morphology (spherical CoV versus bullet-shaped 138 VSV) and possible effects on the conformational display of S on the virion surface, raise questions 139 as to whether the accessibility of epitopes and stoichiometry of antibody neutralization is similar 140 to authentic SARS-CoV-2. A direct comparison with a clinical isolate of SARS-CoV-2 is necessary 141 to establish the utility of VSV-SARS-CoV-2-S\u039421 for assays of viral entry and antibody 142 neutralization.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "134"
        },
        {
            "text": "We designed a high-throughput assay for titrating SARS-CoV-2 that could be applied to 144 multiple cell substrates. Instead of using a plaque assay, which relies on the capacity for a virus 7 to cause cell death, which can vary across cell types, we developed a focus-forming assay (FFA) 146 and viral antigen detection as a measure of infectivity. We propagated SARS-CoV-2 in four 147 different producer cell types (Vero CCL81, Vero E6, Vero-furin, and MA104 cells) and then 148 measured the number and size of foci after staining recipient cells with an anti-S mAb. With SARS-",
            "cite_spans": [
                {
                    "start": 282,
                    "end": 287,
                    "text": "(FFA)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "143"
        },
        {
            "text": "CoV-2 stocks generated from each producer cell type, we observed distinct foci across recipient 150 cell substrates at approximately 30 h post-inoculation (Fig 2A) . We consistently observed the 151 highest viral titers and largest foci sizes with Vero-furin and MA104 cells (Fig 2B-C) . However, 152 the larger foci were more difficult to enumerate on an automated Immunospot reader and required 153 additional manual quality control analysis. Because of this, we used Vero E6 cells for our rapid reduction neutralization test (GRNT) (Fig 2D) .",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 155,
                    "end": 163,
                    "text": "(Fig 2A)",
                    "ref_id": "FIGREF11"
                },
                {
                    "start": 275,
                    "end": 285,
                    "text": "(Fig 2B-C)",
                    "ref_id": "FIGREF11"
                },
                {
                    "start": 535,
                    "end": 543,
                    "text": "(Fig 2D)",
                    "ref_id": "FIGREF11"
                }
            ],
            "section": "149"
        },
        {
            "text": "Neutralization of VSV-SARS-CoV-2-S\u039421 and SARS-CoV-2 by human antibodies.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "161"
        },
        {
            "text": "Members of our group recently identified human mAbs from memory B cells of a SARS-CoV 163 survivor that bind to SARS-CoV-2 S (Pinto et al, 2020) . We tested a subset of these (mAbs 304, ",
            "cite_spans": [
                {
                    "start": 125,
                    "end": 144,
                    "text": "(Pinto et al, 2020)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "162"
        },
        {
            "text": "Many of these mAbs exhibited moderate neutralization activities in the EC50 range of 100 to 500 8 ng/mL (Fig 3C-D) . Nonetheless, we observed the same neutralization trend between VSV-SARS-",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 104,
                    "end": 114,
                    "text": "(Fig 3C-D)",
                    "ref_id": null
                }
            ],
            "section": "170"
        },
        {
            "text": "CoV-2-S\u039421 and SARS-CoV-2 with highly correlated EC50 values (< 2-fold differences). dose-dependently and equivalently inhibited infection of recipient Vero E6 cells (Fig 3E-F) . As 181 expected, hACE2-Fc did not inhibit infection of wild-type VSV confirming that neutralization was 182 specific to the SARS-CoV-2 S protein (Fig S2) . We noted a relatively high concentration of 183 hACE2-Fc was required for inhibition with EC50 values of 29 and 12.6 \u03bcg/ml for VSV-SARS-CoV- ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 166,
                    "end": 176,
                    "text": "(Fig 3E-F)",
                    "ref_id": null
                },
                {
                    "start": 324,
                    "end": 332,
                    "text": "(Fig S2)",
                    "ref_id": "FIGREF11"
                }
            ],
            "section": "172"
        },
        {
            "text": "Neutralization of VSV-SARS-CoV-2-S\u039421 and SARS-CoV-2 by human immune serum.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "188"
        },
        {
            "text": "As part of studies to evaluate immune convalescent plasma as a possible therapy for SARS-CoV- (Table 1) . These samples were pre-192 screened using a commercially available IgG ELISA. We tested each sample for neutralization of 193 VSV-SARS-CoV-2-S\u039421 and SARS-CoV-2 on Vero E6 cells. We observed that sera with ELISA 194 negative or indeterminate results generally showed low inhibitory titers (EC50 <1/100), whereas 195 ELISA positive sera generated a broad range of neutralizing antibody activity (EC50 > 1/200 to 9 >1/1,900) (Fig 4A and C, Fig S3) . Remarkably, neutralization of VSV-SARS-CoV-2-S\u039421 and 197 SARS-CoV-2 was similar across the entire panel of samples (Fig 4B and C, Fig S3) . activity. Here, we generated a high-titer, replication-competent chimeric VSV expressing the 215 SARS-CoV-2 S protein that performs similarly to a SARS-CoV-2 clinical isolate across multiple 216 neutralization tests. As access to BSL3 facilities is limited, the finding that VSV-SARS-CoV-2-S\u039421 217 is neutralized similarly by decoy receptors, mAbs, and polyclonal antibodies in comparison to 218 authentic SARS-CoV-2 is important. This tool will enable academic, government, and industry 219 investigators to rapidly perform assays that interrogate SARS-CoV-2 entry, neutralization, and 220 inhibition at a BSL2 level, which should simplify and expedite the discovery of therapeutic 221 interventions and analysis of functional humoral immune responses.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 94,
                    "end": 103,
                    "text": "(Table 1)",
                    "ref_id": "TABREF0"
                },
                {
                    "start": 529,
                    "end": 551,
                    "text": "(Fig 4A and C, Fig S3)",
                    "ref_id": "FIGREF21"
                },
                {
                    "start": 670,
                    "end": 692,
                    "text": "(Fig 4B and C, Fig S3)",
                    "ref_id": "FIGREF21"
                }
            ],
            "section": "189"
        },
        {
            "text": "Upon recovery of VSV-SARS-CoV-2-SAA, we selected for a mutant, which contained a 21-223 amino acid deletion in the cytoplasmic tail. As truncation of the cytoplasmic tail eliminates the 224 modified KxHxx ER retention signal, we suggest that this mutation facilitates more efficient 225 incorporation of the SARS-CoV-2 S protein into the VSV particles. Although truncation of the 226 cytoplasmic tail of HIV envelope protein resulted in conformational alterations in the ectodomain 227 of the protein (Chen et al., 2015) , based on the extensive neutralization data presented here 228 including correlation to neutralization of a clinical isolate of SARS CoV-2, a 21-amino acid 229 truncation does not appear to substantively alter the structure of the S protein ectodomain. It 230 remains to be determined whether fully wild-type S protein can incorporate efficiently into VSV.",
            "cite_spans": [
                {
                    "start": 501,
                    "end": 520,
                    "text": "(Chen et al., 2015)",
                    "ref_id": "BIBREF6"
                }
            ],
            "ref_spans": [],
            "section": "222"
        },
        {
            "text": "Indeed, similar mutations were generated in the SARS-CoV S protein cytoplasmic tail to boost 232 incorporation into retroviruses and VSV pseudotypes (Fukushi et al., 2005; Giroglou et al., 2004;  11",
            "cite_spans": [
                {
                    "start": 149,
                    "end": 171,
                    "text": "(Fukushi et al., 2005;",
                    "ref_id": null
                },
                {
                    "start": 172,
                    "end": 194,
                    "text": "Giroglou et al., 2004;",
                    "ref_id": null
                },
                {
                    "start": 195,
                    "end": 195,
                    "text": "",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "231"
        },
        {
            "text": "The value of a chimeric virus depends on its capacity to present viral surface antigens in 235 a similar way to its authentic counterpart (Garbutt et al., 2004) . Indeed, the morphology of the 236 bullet-shaped rhabdovirus and the spherical coronavirus and the density and geometry of S 237 protein display could differentially impact antibody engagement and neutralization. Despite this 238 concern, our extensive testing of VSV-SARS-CoV-2-S\u039421 with antibodies and soluble ACE2-Fc 239 proteins showed similar neutralization profiles compared to authentic, fully infectious SARS-CoV- CoV-2. Indeed, convalescent plasma is under investigation as a potential COVID-19 therapeutic 243 (Chen et al., 2020) . Our studies suggest that in addition to testing for anti-S or anti-RBD antibodies 244 (Shen et al., 2020) , neutralization assays with VSV-SARS-CoV-2-S\u039421 may be a convenient and 245 rapid method to obtain functional information about immune plasma preparations to enable 246 prioritization prior to passive transfer to COVID-19 patients.",
            "cite_spans": [
                {
                    "start": 138,
                    "end": 160,
                    "text": "(Garbutt et al., 2004)",
                    "ref_id": null
                },
                {
                    "start": 682,
                    "end": 701,
                    "text": "(Chen et al., 2020)",
                    "ref_id": null
                },
                {
                    "start": 790,
                    "end": 809,
                    "text": "(Shen et al., 2020)",
                    "ref_id": "BIBREF15"
                }
            ],
            "ref_spans": [],
            "section": "231"
        },
        {
            "text": "Coronaviruses possess a roughly 30 kb RNA genome, which requires that they encode a ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "247"
        },
        {
            "text": "Plasmids. The S gene of SARS-CoV-2 isolate Wuhan-Hu-1 (GenBank MN908947.3) was 367 synthesized in two fragments (Integrated DNA Technologies) and inserted into an infectious 368 molecular clone of VSV (Whelan et al., 1995) as previously (Carette et al., 2011; Jae et al., 2014) .",
            "cite_spans": [
                {
                    "start": 201,
                    "end": 222,
                    "text": "(Whelan et al., 1995)",
                    "ref_id": "BIBREF30"
                },
                {
                    "start": 237,
                    "end": 259,
                    "text": "(Carette et al., 2011;",
                    "ref_id": null
                },
                {
                    "start": 260,
                    "end": 277,
                    "text": "Jae et al., 2014)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "366"
        },
        {
            "text": "Modifications to the cytoplasmic tail were assembled identically. Other plasmids were previously 370 described: VSV N, P, L and G expression plasmids (Stanifer et al., 2011; Whelan et al., 1995) , 371 psPAX2 (Addgene), and pLX304-TMPRSS2 (Zang et al., 2020) . ",
            "cite_spans": [
                {
                    "start": 150,
                    "end": 173,
                    "text": "(Stanifer et al., 2011;",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 174,
                    "end": 194,
                    "text": "Whelan et al., 1995)",
                    "ref_id": "BIBREF30"
                },
                {
                    "start": 238,
                    "end": 257,
                    "text": "(Zang et al., 2020)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "369"
        },
        {
            "text": "Following four rounds of selection, phage ELISAs were used to screen 384 clones to identify 430 those that bound specifically to RBD. The complementarity determining regions of Fab-phage 431 clones were decoded by sequencing the variable regions and cloning them into mammalian 432 expression vectors for expression and purification of human IgG1 proteins, as described (Tao et 433 al., 2019) . A subset of the panel of mAbs was tested for neutralization as a part of this study.",
            "cite_spans": [
                {
                    "start": 370,
                    "end": 392,
                    "text": "(Tao et 433 al., 2019)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "429"
        },
        {
            "text": "Another set of mAbs (S304, S306, S309, S310 and S315) were isolated from EBV-435 immortalized memory B cells from a SARS-CoV survivor (Traggiai et al., 2004) and are cross- ",
            "cite_spans": [
                {
                    "start": 134,
                    "end": 157,
                    "text": "(Traggiai et al., 2004)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "434"
        },
        {
            "text": "Protein expression and purification. DNA fragments encoding human ACE2 (hACE2 446 residues 1-615) and mouse ACE2 (mACE2, residues 1-615) were synthesized and cloned into 447 pFM1.2 with a C-terminal HRV-3C protease cleavage site (LEVLFQGP) and a human IgG1 Fc 448 region as previously described (Raj et al., 2013) . We transiently transfected plasmids into ",
            "cite_spans": [
                {
                    "start": 295,
                    "end": 313,
                    "text": "(Raj et al., 2013)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "445"
        },
        {
            "text": "Human immunodeficiency viral vector pseudotyped with the spike envelope of severe acute 537 respiratory syndrome coronavirus transduces human airway epithelial cells and dendritic cells.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "536"
        },
        {
            "text": "Hum Gene Ther 18, 413-422.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "538"
        },
        {
            "text": "Kruse, R.L. (2020). Therapeutic strategies in an outbreak scenario to treat the novel coronavirus 541 originating in Wuhan, China. F1000Research 9, 72.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "540"
        },
        {
            "text": "Lei, C., Qian, K., Li, T., Zhang, S., Fu, W., Ding, M., and Hu, S. (2020) . Neutralization of SARS- ",
            "cite_spans": [
                {
                    "start": 27,
                    "end": 73,
                    "text": "Zhang, S., Fu, W., Ding, M., and Hu, S. (2020)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "543"
        },
        {
            "text": "Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) .",
            "cite_spans": [
                {
                    "start": 69,
                    "end": 100,
                    "text": "Chen, T., Hu, J., et al. (2020)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "575"
        },
        {
            "text": "Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-577 reactivity with SARS-CoV. Nat Commun 11, 1620.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "576"
        },
        {
            "text": "Persson, H., Ye, W., Wernimont, A., Adams, J.J., Koide, A., Koide, S., Lam, R., and Sidhu, S.S.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "579"
        },
        {
            "text": "(2013). CDR-H3 diversity is not required for antigen recognition by synthetic antibodies. J Mol",
            "cite_spans": [],
            "ref_spans": [],
            "section": "580"
        },
        {
            "text": "Biol 425, 803-811. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "581"
        }
    ],
    "bib_entries": {
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Asymptomatic Carrier Transmission of COVID-19",
            "authors": [],
            "year": null,
            "venue": "JAMA",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Deployment of convalescent plasma 489 for the prevention and treatment of COVID-19",
            "authors": [
                {
                    "first": "B",
                    "middle": [
                        "J"
                    ],
                    "last": "Grossman",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Joyner",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "P"
                    ],
                    "last": "Henderson",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Clin Invest",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Ebola virus entry requires the 493 cholesterol transporter Niemann-Pick C1",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "I"
                    ],
                    "last": "Kranzusch",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "J"
                    ],
                    "last": "Griffin",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "M"
                    ],
                    "last": "Ruthel",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Nature",
            "volume": "477",
            "issn": "",
            "pages": "340--343",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic 497 characteristics of HIV-1 envelope glycoprotein",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Kovacs",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Peng",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Rits-Volloch",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Park",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Zablowsky",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "S"
                    ],
                    "last": "Seaman",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Science",
            "volume": "349",
            "issn": "",
            "pages": "191--195",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Cross-neutralization of 587 SARS-CoV and SARS-CoV-2 by a human monoclonal 2 antibody",
            "authors": [
                {
                    "first": "Michael",
                    "middle": [
                        "S"
                    ],
                    "last": "Diamond",
                    "suffix": ""
                },
                {
                    "first": "Katja",
                    "middle": [],
                    "last": "Fink",
                    "suffix": ""
                },
                {
                    "first": "David",
                    "middle": [],
                    "last": "Veesler",
                    "suffix": ""
                },
                {
                    "first": "Davide",
                    "middle": [],
                    "last": "Corti",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nature",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Dipeptidyl peptidase 4 is a functional receptor for the 591 emerging human coronavirus-EMC",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Zaki",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Fouchier",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "A"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Nature",
            "volume": "495",
            "issn": "",
            "pages": "251--254",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "The coronavirus E protein: assembly and beyond",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "R"
                    ],
                    "last": "Ruch",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "E"
                    ],
                    "last": "Machamer",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Viruses",
            "volume": "594",
            "issn": "",
            "pages": "363--382",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Shen",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Yuan",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Xing",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "A recombinant vesicular stomatitis virus 600 bearing a lethal mutation in the glycoprotein gene uncovers a second site suppressor that restores 601 fusion",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Stanifer",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "K"
                    ],
                    "last": "Cureton",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "P"
                    ],
                    "last": "Whelan",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "J Virol",
            "volume": "85",
            "issn": "",
            "pages": "8105--8115",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Specificity, cross-reactivity, and function of 605 antibodies elicited by Zika virus infection",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Minola",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Jaconi",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Mele",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Science",
            "volume": "353",
            "issn": "",
            "pages": "823--826",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Tailored tetravalent antibodies potently and specifically activate 609",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Jarvik",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Wnt/Frizzled pathways in cells, organoids and mice",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "8",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "Human monoclonal antibody 613 combination against SARS coronavirus: synergy and coverage of escape mutants",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "Y"
                    ],
                    "last": "Bakker",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "Q"
                    ],
                    "last": "Bogaards",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Van Deventer",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "PLoS Med",
            "volume": "3",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "Structural insights into coronavirus entry",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Tortorici",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Veesler",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Adv Virus Res",
            "volume": "617",
            "issn": "105",
            "pages": "93--116",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "An efficient method to make human monoclonal 621 antibodies from memory B cells: potent neutralization of SARS coronavirus",
            "authors": [
                {
                    "first": "B",
                    "middle": [
                        "R"
                    ],
                    "last": "Rappuoli",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Lanzavecchia",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Nat Med",
            "volume": "10",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "Antigenicity of the SARS-CoV-2 Spike Glycoprotein",
            "authors": [],
            "year": null,
            "venue": "Cell",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "Site-specific glycan 628 analysis of the SARS-CoV-2 spike",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Watanabe",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Allen",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wrapp",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "S"
                    ],
                    "last": "Mclellan",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Crispin",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Science",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "Efficient recovery of infectious 631 vesicular stomatitis virus entirely from cDNA clones",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "P"
                    ],
                    "last": "Whelan",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "A"
                    ],
                    "last": "Ball",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "N"
                    ],
                    "last": "Barr",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "T"
                    ],
                    "last": "Wertz",
                    "suffix": ""
                }
            ],
            "year": 1995,
            "venue": "Proc Natl Acad Sci U S A",
            "volume": "92",
            "issn": "",
            "pages": "8388--8392",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "S"
                    ],
                    "last": "Mclellan",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF34": {
            "ref_id": "b34",
            "title": "A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-638",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF38": {
            "ref_id": "b38",
            "title": "CoV-2 infection of human small intestinal enterocytes",
            "authors": [],
            "year": null,
            "venue": "Science Immunology",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF39": {
            "ref_id": "b39",
            "title": "Probable Pangolin Origin of SARS-CoV-2 Associated 645 with the COVID-19 Outbreak",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Curr Biol",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF41": {
            "ref_id": "b41",
            "title": "A pneumonia outbreak associated with a new coronavirus of probable bat 649 origin",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "L"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nature",
            "volume": "579",
            "issn": "",
            "pages": "270--273",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "70 2007). Viral pseudotyping assays are limited by the need to express the glycoprotein in trans and 71 preclude forward genetic studies of the viral envelope protein. Expression of the glycoprotein is 72 often accomplished by plasmid transfection, which requires optimization to minimize batch 73 variation. Assays performed with such pseudotyped viruses rely on relative levels of infectivity as 74 measured by a reporter assay without correlation to an infectious titer. It also is unknown as to 75 how the display of S proteins on a heterologous virus impacts viral entry, antibody recognition, 76 and antibody neutralization compared to infectious coronavirus. This question is important 77 because neutralization assays are used to establish correlates of protection for vaccine and 78 antibody-based countermeasures, and most manufacturers lack access to high-containment 79 laboratories to test antibody responses against highly pathogenic coronaviruses including SARS-80 CoV-2.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "154focus-reduction neutralization tests (FRNT) in subsequent experiments.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "high-throughput, eGFP-based neutralization assay for VSV-SARS-CoV-2-S\u039421. In 156 parallel, we developed a high-throughput method to measure neutralization of VSV-SARS-CoV-157 2-S\u039421. As VSV-SARS-CoV-2-S\u039421 encodes an eGFP reporter and viral gene expression is robust, 158 eGFP-positive cells can be quantified 7.5 h post-infection using a fluorescence microscope with 159 automated counting analysis software. This approach enabled the development of an eGFP-",
            "latex": null,
            "type": "figure"
        },
        "FIGREF4": {
            "text": "164 306, 309, and 315) for their ability to inhibit VSV-SARS-CoV-2-S\u039421 and SARS-CoV-2 infections 165 on Vero E6 cells. While three of these mAbs showed poor inhibitory activity, mAb 309 potently 166 neutralized both SARS-CoV-2 and VSV-SARS-CoV-2-S\u039421(Fig 3A-B)with similar EC50 values 167 between the two assays (81 and 67 ng/mL for SARS-CoV-2 and VSV-SARS-CoV-2-S\u039421, 168 respectively). To broaden the test panel, we evaluated the activity of a panel of mAbs generated 169 as part of a phage display library (Sachev Sidhu, unpublished data) by both FRNT and GRNT.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF5": {
            "text": "Neutralization by human ACE2-Fc receptor decoy proteins. Human ACE2 (hACE2) is 174 an entry receptor for both SARS-CoV and SARS-CoV-2 (Letko et al., 2020; Li et al., 2005; Li et 175 al., 2003; Wrapp et al., 2020). As a soluble hACE2-Fc decoy protein has been proposed as a 176 therapeutic for SARS-CoV-2 (Kruse, 2020), in part based on its ability to inhibit SARS-CoV 177 infection in cell culture (Moore et al., 2004), we tested whether hACE2-Fc could inhibit infection 178 of VSV-SARS-CoV-2-S\u039421 and SARS-CoV-2 using our FRNT and GRNT assays. When pre-mixed 179 with VSV-SARS-CoV-2-S\u039421 or SARS-CoV-2, hACE2-Fc, but not murine ACE2-Fc (mACE2-Fc),",
            "latex": null,
            "type": "figure"
        },
        "FIGREF7": {
            "text": "and SARS-CoV-2, respectively. Thus, although soluble hACE2-Fc decoy proteins similarly 185 inhibit infection of VSV-SARS-CoV-2-S\u039421 and SARS-CoV-2, the potency is less than anticipated, 186 which suggests that the receptor-binding domain (RBD) on the S protein on the surface of both 187 viruses may not be fully accessible in solution.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF8": {
            "text": "(Bloch et al., 2020), we obtained 42 serum samples from 20 individuals at 191 different time points after the onset of COVID-19 symptoms",
            "latex": null,
            "type": "figure"
        },
        "FIGREF9": {
            "text": "CoV-2 neutralization assays are highly 199 correlative. We determined the extent to which the VSV-SARS-CoV-2-S\u039421 and SARS-CoV-2 200 neutralization tests correlated with each other. We compared the GRNT and FRNT EC50 values 201 obtained in assays with mAbs, polyclonal sera, and soluble ACE2 protein (Fig 5). For the samples 202 with neutralizing activity, we observed a remarkably strong correlation between the two assays (r 203 = 0.9285; p < 0.001). Moreover, all 11 of the samples that were deemed non-neutralizing in one 204 assay had the same result in the second assay. Together, these results establish the utility of 205 using VSV-SARS-CoV-2-S\u039421 as a surrogate for authentic SARS-CoV-2 infection in entry 206 inhibition and neutralization studies.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF10": {
            "text": "pathogens have caused numerous epidemics and several pandemics over 210 the last century. The most recent example, SARS-CoV-2, has spread to nearly every country in 211 the world in just a few months, causing millions of infections and hundreds of thousands of deaths 212 (https://www.worldometers.info/coronavirus/). Rapid responses to viral outbreaks and generation 213 of countermeasures require readily accessible tools to facilitate study and evaluate antiviral 214",
            "latex": null,
            "type": "figure"
        },
        "FIGREF11": {
            "text": "Thus, VSV-SARS-CoV-2-S\u039421, despite the structural differences of the virion, provides a useful 241 tool for screening antibodies, entry-based antiviral agents, and vaccine responses against SARS-",
            "latex": null,
            "type": "figure"
        },
        "FIGREF13": {
            "text": "248proofreading enzyme (ExoN in nsp14)(Denison et al., 2011)  to counteract the error rate of the 249 viral RNA-dependent RNA polymerase. The lack of such proofreading enzymes in the genomes 250 of rhabdoviruses suggests that selection of escape mutants to inhibitors of the coronavirus S 251 protein will be faster in VSV-SARS-CoV-2, which further increases the utility of this chimeric virus.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF14": {
            "text": "FRNT and GRNT assays can be used to establish evidence of prior SARS-CoV-2 infection 253 or vaccination, as well as determine waning of functional responses over time, as the likelihood 254 of cross-neutralizing responses with other cosmopolitan coronaviruses (e.g., HCoV-229E and 255 HCoV-OC43) is exceedingly low. Overall, VSV-SARS-CoV-2-S\u039421 and our FRNT and GRNT 256 assays, can facilitate the development and evaluation of antibody-or entry-based 257 countermeasures against SARS-CoV-2 infection.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF15": {
            "text": "Project Agency (HR001117S0019) and gifts from Washington University in 263 Saint Louis. J.B.C. is supported by a Helen Hay Whitney Foundation postdoctoral fellowship. We 264 thank James Rini for providing RBD used to detect phage display mAbs. Some of the .C. performed SARS-CoV-2 neutralization experiments. P.W.R. generated and 269 characterized VSV-SARS-CoV-2-S\u039421 and performed neutralization experiments. R.E.C., Z.L., 270 L.M.B., M.A.T., S.D., and Q.Z. provided experimental assistance. S.T., L.D., and D.W. prepared 271 RNAseq libraries and assembled the VSV-SARS-CoV-2-S\u039421 sequence. H.Z. and D.H.F. 272 generated and provided purified proteins, D.C. and H.W.V. provided the recombinant mAbs, S.M. 273 M.U. S.S., and G.A. provided other recombinant mAbs, E.S.T. and J.P.H. identified and provided 274 the human immune serum. M.X.G.I. helped with automated microscope use and analysis. J.B.C, 275 P.W.R., S.P.J.W., and M.S.D. wrote the initial draft, with the other authors providing .S.D. is a consultant for Inbios, Vir Biotechnology, NGM Biopharmaceuticals, and on the 280 Scientific Advisory Board of Moderna. D.C. and H.W.V. are employees of Vir Biotechnology Inc.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF16": {
            "text": "281and may hold shares in Vir Biotechnology Inc. S.P.J.W. and P.W.R. have filed a disclosure with 282 Washington University for the recombinant VSV.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF17": {
            "text": "Generation and characterization of an infectious VSV-SARS-CoV-2 286 chimera. (A) A schematic diagram depicting the genomic organization of the VSV recombinants, 287 shown 3' to 5' are the leader region (Le), eGFP, nucleocapsid (N), phosphoprotein (P), matrix (M), 288 glycoprotein (G) or SARS-CoV-2 S, large polymerase (L), and trailer region (Tr). (Right panel) 289 Infection of Vero CCL81 cells with supernatant from cells transfected with the eGFP reporter VSV-290 SARS-CoV-2-SAA. Images were acquired 44 hours post-infection (hpi) using a fluorescence 291 microscope, and GFP and transmitted light images were merged using ImageJ. (Bottom panel) 292 Alignment of the cytoplasmic tail of the VSV-SARS-CoV-2-SAA and the sequence resulting from 293 forward genetic selection of a mutant, which truncated the cytoplasmic tail by 21 amino acids. 294 Mutations deviating from the wild-type spike are indicated in red, and an asterisk signifies a 295 mutation to a stop codon. (B) Plaque assays were performed to compare the spread of VSV-296 SARS-CoV-2-SAA rescue supernatant and VSV-SARS-CoV-2-S\u039421 on Vero CCL81, Vero E6, 297 Vero-furin, and MA104 cells. Plates were scanned on a biomolecular imager and expression of 298 eGFP is shown 92 hpi (representative images are shown; n>3 except for SAA on Vero E6, Vero-299 furin, and MA104 cells). (C) The indicated cell types were infected with VSV-SARS-CoV-2-S\u039421 at 300 an MOI of 0.5. Cells and supernatants were harvested at 24 hpi and titrated on MA104 cells (data 301 are pooled from three or more independent experiments). (D) (Top panel) The indicated cells 302 were infected with VSV-SARS-CoV-2-S\u039421 at an MOI of 2. Images were acquired 7.5 hpi using a 303 fluorescence microscope and GFP, and transmitted light images were processed and merged 304 using ImageJ (data are representative of two independent experiments). (Bottom panel) Plaque 305 assays were performed on the indicated cell types using VSV-SARS-CoV-2-S\u039421. Images showing 306 GFP expression were acquired 48 hpi using a biomolecular imager (data are representative of at 307 least 3 independent experiments). (E) Western blotting was performed on concentrated VSV-308 SARS-CoV-2-S\u039421 and wild-type VSV particles on an 8% non-reducing SDS-PAGE gel. S1 was 309 detected using a cross-reactive anti-SARS-CoV mAb (CR3022) (data are representative of two 310 14 independent experiments). (F) BSRT7/5 cells were inoculated at an MOI of 10 with VSV-eGFP, 311 G-complemented VSV-SARS-CoV-2-S\u039421, or mock infected (not shown), and metabolically 312 labeled with [ 35 S] methionine and cysteine for 20 h starting at 5 hpi in the presence of actinomycin 313 D. Viral supernatants were analyzed by SDS-PAGE. A representative phosphor-image is shown 314 from two independent experiments. An asterisk indicates a band that also was detected in the 315 mock lane (not shown). (G) Purified VSV-WT and VSV-SARS-CoV-2-S\u039421 particles were 316 subjected to negative stain electron microscopy. Prefusion structures of each respective 317 glycoprotein are modeled above each EM image (PDB: 5I2S and 6VSB).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF18": {
            "text": "Development of a SARS-CoV-2 focus-forming assay and a VSV-SARS-319 CoV-2-S\u039421 eGFP-reduction assay. (A) Representative focus forming assay images of viral 320 stocks generated from each producer cell type (top) were developed on the indicated cell 321 substrates (indicated on the left side). Data are representative of two independent experiments.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF19": {
            "text": "obtained in (A) were counted (B) and the size was determined (C) using an ImmunoSpot 323 plate reader (* P < 0.05, ** P < 0.01, *** P < 0.001 1 by One-way ANOVA with Tukey's multiple 324 comparisons test). (D) Representative serial dilution series of VSV-SARS-CoV-2-S\u039421 on Vero E6 325 cells. The total number of infected cells per well was quantified using an automated microscope. 326 Insets of enhanced magnification are shown in red. Data are representative of two independent 327 experiments.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF20": {
            "text": "Neutralization of VSV-SARS-CoV-2-S\u039421 and SARS-CoV-2 by human 329 monoclonal antibodies and hACE2 decoy receptors. A-B. Cross-reactive mAbs isolated from 330 a SARS-CoV survivor were tested for neutralizing activity against SARS-CoV-2 (A) or VSV-331 SARS-CoV-2-S\u039421 (B) (n=2 and 3, respectively). C-D. SARS-CoV-2 RBD-specific antibodies 332 obtained from a phage library were tested for their capacity to neutralize SARS-CoV-2 (C) or VSV-333 SARS-CoV-2-S\u039421 (D) (n=2 and 2, respectively). E-F. hACE2-Fc or mACE2-Fc were tested for 334 their neutralization activity against SARS-CoV-2 (E) or VSV-SARS-CoV-2-S\u039421 (F) (n=2 and 3, 335 respectively).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF21": {
            "text": "Human immune serum neutralization of SARS-CoV-2 and VSV-SARSand 2, respectively). (C) EC50 values of all human serum tested for neutralization of SARS-340CoV-2 and VSV-SARS-CoV-2-S\u039421. Differences in the geometric mean or median titers were less 341 than 3-fold between FRNT and GRNT assays.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF22": {
            "text": "Correlation analysis of neutralization of SARS-CoV-2 and VSV-SARS-CoV-343 2-S\u039421. EC50 values determined in Fig 3A-D, and 4A-B were used to determine correlation 344 between neutralization assays. Spearman's correlation r and p values are indicated. Rescue of a chimeric VSV expressing the SARS-CoV-2 S protein and 348 forward genetic selection of a gain-of-function mutant. (A) BSRT7/5 cells were infected with 349 vaccinia virus vTF7-3, transfected with plasmids allowing T7-driven expression of VSV N, P, L, 350 and G, and an infectious molecular cDNA of VSV-SARS-CoV-2-SAA to produce replication-351 competent VSV-SARS-CoV-2-SAA. (B) Alignment of the membrane proximal region, 352 transmembrane domain, and cytoplasmic tail of various recombinants that were generated. 353 Successful rescue and indication of spread are noted. (C) VSV-SARS-CoV-2-SAA was passaged 354 iteratively on Vero CCL81 cells. Several clones were plaque-purified and amplified on Vero 355 CCL81 cells. RNA from infected cells was extracted and deep sequenced to identify mutants.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF23": {
            "text": "Inhibition of VSV-SARS-CoV-2-S\u039421 but not VSV with hACE2-Fc receptor 357 decoy proteins. VSV-SARS-CoV-2-S\u039421 and VSV were incubated with the indicated human or 358 murine ACE2-Fc receptor decoy proteins, and virus-antibody mixtures were used to infect Vero 359 E6 cells in a GRNT assay. Data are representative of three independent experiments.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF24": {
            "text": "Human immune serum neutralization of SARS-CoV-2 and VSV-SARS-361CoV-2-S\u039421. As described inFig 4,human serum samples from PCR confirmed SARS-CoV-",
            "latex": null,
            "type": "figure"
        },
        "FIGREF25": {
            "text": "Cells were maintained in humidified incubators at 34 or 37\u00b0C and 5% CO2 in the 373 indicated media. BSRT7/5, Vero CCL81, Vero E6, Vero E6-TMPRSS2, A549, Caco-2, Caco-2 374 BBe1, Huh7, HepG2, Hela, BHK-21, HEK293, and HEK293T were maintained in DMEM (Corning 375 or VWR) supplemented with glucose, L-glutamine, sodium pyruvate, and 10% fetal bovine serum 376 (FBS). Vero-furin cells (Mukherjee et al., 2016) also were supplemented with 5 \u03bcg/ml of blasticidin. 377 MA104 cells were maintained in Medium 199 (Gibco) containing 10% FBS. HT-29 cells were 378 cultured in complete DMEM/F12 (Thermo-Fisher) supplemented with sodium pyruvate, non-379 essential amino acids, and HEPES. Vero E6-TMPRSS2 cells were generated using a lentivirus 380 vector. Briefly, HEK293T producer cells were transfected with pLX304-TMPRSS2, pCAGGS-381VSV-G, and psPAX2, and cell culture supernatants were collected at 48 hours and clarified by 382 centrifugation at 1,000 x g for 5 min. The resulting lentivirus was used to infect Vero E6 cells for 383 24 h, and cells were selected with 40 \u03bcg/ml blasticidin for 7 days.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF26": {
            "text": "VSV. Recovery of recombinant VSV was performed as described(Whelan   385   et al., 1995). Briefly, BSRT7/5 cells were inoculated with vaccinia virus vTF7-3 and subsequently 386 transfected with T7-expression plasmids encoding VSV N, P, L, and G, and an antigenomic copy 387 of the viral genome. Cell culture supernatants were collected at 56-72 h, clarified by centrifugation 388 (5 min at 1,000 x g), and filtered through a 0.22 \u03bcm filter. Virus was plaque-purified on Vero CCL81389 cells in the presence of 25 \u03bcg/ml of cytosine arabinoside (TriLink BioTechnologies), and plaques 390 in agarose plugs were amplified on Vero CCL81 cells. Viral stocks were amplified on MA104 cells 391 at an MOI of 0.01 in Medium 199 containing 2% FBS and 20 mM HEPES pH 7.7 (Millipore Sigma) 392 at 34\u00b0C. Viral supernatants were harvested upon extensive cytopathic effect and clarified of cell 393 debris by centrifugation at 1,000 x g for 5 min. Aliquots were maintained at -80\u00b0C. 394 Next generation sequencing. Total RNA was extracted from Vero CCL81 cells infected 395 with VSV-SARS-CoV-2-S\u039421 using Trizol (Invitrogen) according to the manufacturer's protocol. 396 RNA was used to generate next generation sequencing libraries using TruSeq Stranded Total 397 RNA library kit with Ribo Zero ribosomal subtraction (Illumina). The libraries were quantified using 398 a bioanalyzer (Agilent) and pooled at an equal molar concentration and used to generate paired 399 end 250 bp reads on an MiSeq (Illumina). Raw sequencing data was processed using fastp 400 v0.20.0 to trim adapters and filter out reads with a quality score < 30. Alignment of each sample 401 to VSV and SARS CoV-2 sequence was performed using bbmap v38.79. Mapped reads were 402 extracted using samtools 1.9 and used for de novo assembly by SPAdes v3.13.0. Consensus 403 sequences for each RNA sample were generated by aligning contigs to the reference plasmid 404 sequence pVSV(1+)-eGFP-SARS-CoV-2-S with SnapGene v5.0. 405 Western blotting. Purified VSV were incubated in non-reducing denaturation buffer (55 406 mM Tris-HCl pH 6.8, 1.67 % (w/v) SDS, 7.5 % (w/v) glycerol) at 100\u00b0C for 5 min. Viral proteins 407 were separated on a 8% acrylamide gel, transferred onto a nitrocellulose membrane, and 408 incubated with human anti-SARS antibody CR3022 diluted in Tris-buffer saline containing 1%409Tween-20 (TBS-T) and 5% milk, followed by incubation with HRP-conjugated goat anti-human 410 antibody (Abcam) diluted in TBS-T containing 1% milk. HRP activity was visualized using the 411 Pierce ECL Western blotting kit (Thermo Scientific) and imaged with a ChemiDocTM MP Imager 412 (Bio-Rad).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF27": {
            "text": "Metabolic radiolabeling of virions. To generate high titer stocks of VSV-SARS-CoV-2, 414 BSRT7/5 cells were transfected with pCAGGS-VSV-G in Opti-MEM (Gibco) using Lipofectamine 415 2000 (Invitrogen) and infected 7 h later with VSV-SARS-CoV-2-S\u039421 at an MOI of 0.1 in DMEM 416 containing 2% FBS and 20 mM HEPES pH 7.7. Viral stocks were collected at 48 hpi, and used to ), and analyzed by SDS-PAGE and detected by phosphoimage 421 analysis (Li et al., 2006).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF28": {
            "text": "Transmission electron microscopy. Purified viruses were adhered to glow-discharged,423 carbon-coated copper grids. Samples were stained with 2% (w/v) phosphotungstic acid, pH 7.1, 424 in H2O and viewed on a JEOL 1200 EX transmission electron microscope (JEOL USA Inc.) 425 equipped with an AMT 8-megapixel digital camera and AMT Image Capture Engine V602 426 software (Advanced Microscopy Techniques).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF29": {
            "text": "Monoclonal antibodies. Phage-displayed Fab libraries were panned against immobilized 428 SARS-CoV-2 spike RBD in multiple rounds using established methods (Persson et al., 2013).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF30": {
            "text": "436reactive to SARS-CoV-2(Pinto et al, in press). Recombinant antibodies were expressed in 437 ExpiCHO cells transiently co-transfected with plasmids expressing the heavy and light chain as 438 previously described(Stettler et al., 2016).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF31": {
            "text": "Human sera. Human samples were collected from PCR-confirmed COVID-19 patients.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF32": {
            "text": "Serum samples were obtained by routine phlebotomy at different days post symptom onset 441 (range: day 5 -20). Samples were prescreened by the Euroimmun anti-SARS-CoV-2 IgG ELISA 442 (Lubeck, Germany), a qualitative assay with the Food and Drug Administration Emergency Use 443 20 Authorization that detects antibodies to the SARS-CoV-2 S protein. This study was approved by 444 the Mayo Clinic Institutional Review Board.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF33": {
            "text": "Expi293F cells and harvested cell supernatants 4 days post transfection. Secreted hACE2-Fc and 450 mACE2-Fc proteins were purified by protein A chromatography (Goldbio).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF34": {
            "text": "451 GFP-reduction neutralization test. Patient samples were heat-inactivated at 56\u00b0C for 30 452 min. Indicated dilutions of samples were incubated with 10 2 PFU of VSV-SARS-CoV-2-S\u039421 for 1 453 h at 37\u00b0C. Antibody-virus complexes were added to Vero E6 cells in 96-well plates and incubated 454 at 37\u00b0C for 7.5 h. Cells subsequently were fixed in 2% formaldehyde containing 10 \u00b5g/mL Hoechst 455 33342 nuclear stain (Invitrogen) for 45 min at room temperature, when fixative was replaced with 456 PBS. Images were acquired with the InCell 2000 Analyzer (GE Healthcare) automated 457 microscope in both the DAPI and FITC channels to visualize nuclei and infected cells (i.e., eGFP-458 positive cells), respectively (4X objective, 4 fields per well, covering the entire well). Images were 459 analyzed using the Multi Target Analysis Module of the InCell Analyzer 1000 Workstation 460 Software (GE Healthcare). GFP-positive cells were identified in the FITC channel using the top-461 hat segmentation method and subsequently counted within the InCell Workstation software. The 462 sensitivity and accuracy of GFP-positive cell number determinations were validated using a serial 463 dilution of virus. A background number of GFP+ cells was subtracted from each well using an 464 average value determined from at least 4 uninfected wells. Data were processed using Prism 465 software (GraphPad Prism 8.0). ACE2 neutralization assays using VSV-SARS-CoV-2-S\u039421 were 466 conducted similarly but using an MOI of 1. 467 21 Focus reduction neutralization test. SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2020 468 was obtained from the Centers for Disease Control and Prevention (gift of Natalie Thornburg). 469 Virus was passaged in the indicated producer cells. Indicated dilutions of mAbs, sera, or protein 470 were incubated with 10 2 FFU of SARS-CoV-2 for 1 h at 37\u00b0C. Antibody-virus complexes were 471 added to indicated cell monolayers in 96-well plates and incubated at 37\u00b0C for 1 h. Subsequently, 472 cells were overlaid with 1% (w/v) methylcellulose in MEM supplemented with 2% FBS. Plates 473 were harvested 30 h later by removing overlays and fixed with 4% paraformaldehyde in PBS for 474 20 min at room temperature. Plates were washed and sequentially incubated with 1 \u00b5g/mL of 475 CR3022 anti-S antibody (ter Meulen et al., 2006; Yuan et al., 2020) and HRP-conjugated goat 476 anti-human IgG in PBS supplemented with 0.1% saponin and 0.1% BSA. SARS-CoV-2-infected 477 cell foci were visualized using TrueBlue peroxidase substrate (KPL) and quantitated on an 478 ImmunoSpot microanalyzer (Cellular Technologies). Data were processed using Prism software 479 (GraphPad Prism 8.0).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF35": {
            "text": "Statistical analyses. All statistical tests were performed using GraphPad Prism 8.0 481 software as described in the indicated figure legends. 482 498 499 Chen, L., Xiong, J., Bao, L., and Shi, Y. (2020). Convalescent plasma as a potential therapy for 500 COVID-19. Lancet Infect Dis 20, 398-400. 501 502 Denison, M.R., Graham, R.L., Donaldson, E.F., Eckerle, L.D., and Baric, R.S. (2011).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF36": {
            "text": "Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity. RNA504 biology 8, 270-279. 505 506 Fukushi, S., Mizutani, T., Saijo, M., Kurane, I., Taguchi, F., Tashiro, M., and Morikawa, S. (2006).507 Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of 508 neutralizing antibody responses to SARS-CoV. J Med Virol 78, 1509-1512. 509 510 Fukushi, S., Mizutani, T., Saijo, M., Matsuyama, S., Miyajima, N., Taguchi, F., Itamura, S., Kurane, 511 I., and Morikawa, S. (2005). Vesicular stomatitis virus pseudotyped with severe acute respiratory 512 syndrome coronavirus spike protein. J Gen Virol 86, 2269-2274. 513 514 Garbutt, M., Liebscher, R., Wahl-Jensen, V., Jones, S., Moller, P., Wagner, R., Volchkov, V., 515 Klenk, H.D., Feldmann, H., and Stroher, U. (2004). Properties of replication-competent vesicular 516 stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 78, , T., Cinatl, J., Jr., Rabenau, H., Drosten, C., Schwalbe, H., Doerr, H.W., and von Laer, 520 D. (2004). Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S 521 protein. J Virol 78, 9007-9015. 522 523 Guan, W.J., Ni, Z.Y., Hu, Y., Liang, W.H., Ou, C.Q., He, J.X., Liu, L., Shan, H., Lei, C.L., Hui, 524 D.S.C., et al. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. , M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., Schiergens, 528 T.S., Herrler, G., Wu, N.H., Nitsche, A., et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 529 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181, 271-280.530 531Janssen, H.,Damme, M., Saftig, P., et al. (2014). Virus entry. Lassa virus entry requires a",
            "latex": null,
            "type": "figure"
        },
        "FIGREF37": {
            "text": "pseudotyped virus by recombinant ACE2-Ig. Nat Commun 11, 2070.545 546Letko, M.,Marzi, A., and Munster, V. (2020). Functional assessment of cell entry and receptor 547 usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nature microbiology 5, 562-569.548 549Li, F.,Li, W., Farzan, M., and Harrison, S.C. (2005). Structure of SARS coronavirus spike550 receptor-binding domain complexed with receptor. Science 309, 1864-1868. 551 552 Li, J., Wang, J.T., and Whelan, S.P. (2006). A unique strategy for mRNA cap methylation used 553 by vesicular stomatitis virus. Proc Natl Acad Sci U S A 103, 8493-8498. 554 555 Li, W., Moore, M.J., Vasilieva, N., Sui, J., Wong, S.K., Berne, M.A., Somasundaran, M., Sullivan, 556 J.L., Luzuriaga, K., Greenough, T.C., et al. (2003). Angiotensin-converting enzyme 2 is a 557 functional receptor for the SARS coronavirus. Nature 426, 450-454. 558 559 Lontok, E., Corse, E., and Machamer, C.E. (2004). Intracellular targeting signals contribute to 560 localization of coronavirus spike proteins near the virus assembly site. J Virol 78, 5913-5922. 561 562 McBride, C.E., Li, J., and Machamer, C.E. (2007). The cytoplasmic tail of the severe acute 563 respiratory syndrome coronavirus spike protein contains a novel endoplasmic reticulum retrieval 564 signal that binds COPI and promotes interaction with membrane protein. J Virol 81, 2418-2428. 565 566 Moore, M.J., Dorfman, T., Li, W., Wong, S.K., Li, Y., Kuhn, J.H., Coderre, J., Vasilieva, N., Han, 567 Z., Greenough, T.C., et al. (2004). Retroviruses pseudotyped with the severe acute respiratory 568 syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting 569 enzyme 2. J Virol 78, 10628-10635. 570 571 Mukherjee, S., Sirohi, D., Dowd, K.A., Chen, Z., Diamond, M.S., Kuhn, R.J., and Pierson, T.C. 572 (2016). Enhancing dengue virus maturation using a stable furin over-expressing cell line. Virology 573 497, 33-40.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF38": {
            "text": "sequence (membrane proximal region, transmembrane domain, cytoplasmic tail)",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "Human serum ELISA IgG.Legend toTable 1: Serum samples from 20 individuals were collected at different time points post onset of COVID-19 symptoms, were screened using two ELISA assays (Euroimmun or Epitope). The serum numbers correspond to those ofFigures 4 and S3. IgG index values were calculated by dividing the O.D. of the serum sample by a reference O.D. control, and ratios were interpreted using the following criteria as recommended by the manufacturer: Negative (-) <0.8, Indeterminate (+/-) 0.8-1.1, Positive (+) \u22651.1.",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}